New 2-Drug HIV Regimen Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. Study Shows Patients Commonly Misdiagnosed with Multiple Sclerosis

Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers. Read more.

4. FDA Approves New Osteoporosis Therapy for Postmenopausal Women

Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis. Read more.

3. Revcovi: A New Treatment Option for ADA-SCID

Adenosine deaminase is an ultra-rare and inherited disorder that is detrimental to the immune system and causes severe combined immune deficiency. Read more.

2. Senate Hearing Addresses Role of Pharmacy Benefit Managers in Drug Pricing

On Tuesday, a US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients. Read more.

1.FDA OKs 2-Drug HIV Treatment for Antiretroviral Therapy-Naïve Patients

With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet. Read more.